ReviewJournal of molecular neuroscience : MN2025
Ferroptosis: Disease Associations and Therapeutic Target Exploration.
Review in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The therapeutic potential of Piezo1 channel-mediated ferroptosis and its inhibitor.Apoptosis : an international journal on programmed cell death · 2026Review
- Review
- Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.Frontiers in pharmacology · 2026Review
- Ferroptosis-Mediated Cell-Specific Damage: Molecular Cascades and Therapeutic Breakthroughs in Diabetic Retinopathy.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ferroptosis, a distinct form of cell death, is transforming the understanding of complex diseases such as cancer, neurodegenerative disorders. Driven by iron accumulation and lipid peroxidation, ferroptosis offers significant therapeutic potential by selectively targeting diseased cells. Ferroptosis is closely associated with renal impairment, metabolic disease, and neurological disorders. The current focus is on understanding the signaling pathways of ferroptosis to precisely regulate the ferroptosis mechanism. For example, ferroptosis increases intracellular selenium content and synergistically activates transcription factors transcription factor AP-2 gamma and specificity protein 1 to promote glutathione peroxidase-4 expression (GPX4). Despite its broad therapeutic potential, significant challenges remain, particularly in uncovering the detailed molecular mechanisms of ferroptosis and minimizing off-target effects. However, in the past two years, there has been a few comprehensive reviews on the exploration of therapeutic targets related to ferroptosis in disease treatment. This article provides a summary of the current understanding of ferroptosis mechanisms, its links to various diseases, and the exploration of potential therapeutic targets. By elucidating the complex molecular pathways of ferroptosis and highlighting its role in disease progression, we gain new insights for potential therapeutic strategies. This underscores the substantial theoretical significance of targeting ferroptosis for treatment purposes.
Indexed as
Identifiers
40515876What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.